Skip to main content
Premium Trial:

Request an Annual Quote

Evotec, Jain Foundation Expand Muscular Dystrophy Collaboration

NEW YORK (GenomeWeb News) – Evotec and the Jain Foundation today said they have extended and expanded their 2012 research collaboration aimed at dysferlinopathy.

Terms of the expanded deal were not disclosed.

Evotec and Jain started a research project in 2012 to develop a cell-based high-throughput screening assay using dysferlin-deficient cells with the goal of identifying compounds that can improve the well-being of dysferlin-deficient muscle cells.

Mutations in or the absence of dysferlin, a protein produced by the dysferlin gene, cause types of muscular dystrophy called limb-girdle muscular dystrophy type 2B and Miyoshi Myopathy.

"This collaboration highlights both the increasing role that foundations play in delivering solutions for unmet medical needs and also how Evotec's broad and comprehensive discovery platform can be leveraged in support of these goals in a highly efficient and effective manner," Mario Polywka, COO of Evotec, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more